ERYDERM Drug Patent Profile
✉ Email this page to a colleague
When do Eryderm patents expire, and what generic alternatives are available?
Eryderm is a drug marketed by Arbor Pharms Inc and is included in one NDA.
The generic ingredient in ERYDERM is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eryderm
A generic version of ERYDERM was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for ERYDERM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 6,219 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ERYDERM at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ERYDERM
US Patents and Regulatory Information for ERYDERM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arbor Pharms Inc | ERYDERM | erythromycin | SOLUTION;TOPICAL | 062290-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |